CN109563051B - 作为pde4抑制剂的并环类化合物 - Google Patents
作为pde4抑制剂的并环类化合物 Download PDFInfo
- Publication number
- CN109563051B CN109563051B CN201780046018.7A CN201780046018A CN109563051B CN 109563051 B CN109563051 B CN 109563051B CN 201780046018 A CN201780046018 A CN 201780046018A CN 109563051 B CN109563051 B CN 109563051B
- Authority
- CN
- China
- Prior art keywords
- compound
- mmol
- room temperature
- reaction mixture
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610706073 | 2016-08-22 | ||
| CN2016107060731 | 2016-08-22 | ||
| PCT/CN2017/098462 WO2018036470A1 (zh) | 2016-08-22 | 2017-08-22 | 作为pde4抑制剂的并环类化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109563051A CN109563051A (zh) | 2019-04-02 |
| CN109563051B true CN109563051B (zh) | 2024-06-11 |
Family
ID=61246426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780046018.7A Active CN109563051B (zh) | 2016-08-22 | 2017-08-22 | 作为pde4抑制剂的并环类化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10532986B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3502099B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7050054B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN109563051B (cg-RX-API-DMAC10.html) |
| ES (1) | ES2852098T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018036470A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7237973B2 (ja) * | 2018-01-29 | 2023-03-13 | メッドシャイン ディスカバリー インコーポレイテッド | 1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン系化合物の結晶形及びその製造方法 |
| WO2021000934A1 (zh) * | 2019-07-04 | 2021-01-07 | 南京明德新药研发有限公司 | 一种苯并咪唑-2-酮类化合物的晶型、溶剂化物、溶剂化物的晶型及它们的制备方法 |
| EP4101848A4 (en) * | 2020-02-24 | 2023-07-26 | Suzhou Longbotai Pharmaceuticals Co., Ltd. | Pde4 inhibitor compound and medical use thereof |
| CN116783181B (zh) * | 2021-04-12 | 2026-01-30 | 上海瑛派药业有限公司 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| CN101528712A (zh) * | 2006-08-26 | 2009-09-09 | 艾博特股份有限两合公司 | 取代的苯并咪唑酮衍生物、包含它们的药物以及其用途 |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| WO2012021382A1 (en) * | 2010-08-12 | 2012-02-16 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| CN105407888A (zh) * | 2013-06-21 | 2016-03-16 | 齐尼思表观遗传学公司 | 新双环溴结构域抑制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115644B2 (en) * | 2002-09-13 | 2006-10-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds |
| MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| JP2014114308A (ja) | 2014-01-31 | 2014-06-26 | Celgene Corp | (+)−2−[1−(3−エトキシ−4−メトキシフェニル)−2−メチルスルホニルエチル]−4−アセチルアミノイソインドリン−1,3−ジオンを含む固形物形態、その組成物およびその使用 |
| AR101196A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Compuestos de pirimidina sustituidos |
-
2017
- 2017-08-22 WO PCT/CN2017/098462 patent/WO2018036470A1/zh not_active Ceased
- 2017-08-22 CN CN201780046018.7A patent/CN109563051B/zh active Active
- 2017-08-22 JP JP2019510933A patent/JP7050054B2/ja active Active
- 2017-08-22 EP EP17842893.4A patent/EP3502099B1/en active Active
- 2017-08-22 US US16/325,626 patent/US10532986B2/en active Active
- 2017-08-22 ES ES17842893T patent/ES2852098T3/es active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| CN101528712A (zh) * | 2006-08-26 | 2009-09-09 | 艾博特股份有限两合公司 | 取代的苯并咪唑酮衍生物、包含它们的药物以及其用途 |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| WO2012021382A1 (en) * | 2010-08-12 | 2012-02-16 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| CN105407888A (zh) * | 2013-06-21 | 2016-03-16 | 齐尼思表观遗传学公司 | 新双环溴结构域抑制剂 |
Non-Patent Citations (1)
| Title |
|---|
| "Apremilast: First Global Approval";Raewyn M. Poole等;《Drugs》;第74卷;825–837 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3502099A4 (en) | 2020-03-04 |
| US10532986B2 (en) | 2020-01-14 |
| EP3502099B1 (en) | 2020-12-09 |
| JP7050054B2 (ja) | 2022-04-07 |
| US20190210975A1 (en) | 2019-07-11 |
| WO2018036470A1 (zh) | 2018-03-01 |
| JP2019529364A (ja) | 2019-10-17 |
| ES2852098T3 (es) | 2021-09-13 |
| CN109563051A (zh) | 2019-04-02 |
| EP3502099A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113286794B (zh) | Kras突变蛋白抑制剂 | |
| CN115192577A (zh) | Kras突变蛋白抑制剂 | |
| EP3333157B1 (en) | Vinyl compounds as fgfr and vegfr inhibitors | |
| CN110446712A (zh) | 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物 | |
| JP6724246B2 (ja) | チオフェン化合物、その合成方法及び医療における応用 | |
| RU2743126C2 (ru) | Ингибитор pde4 | |
| JP2020508342A (ja) | 三環式化合物及びその応用 | |
| EP3502099B1 (en) | Cyclic compound acting as pde4 inhibitor | |
| KR102547709B1 (ko) | 아제티딘 유도체 | |
| EP3567028B1 (en) | Biphenyl compound as ccr2/ccr5 receptor antagonist | |
| CN111556869A (zh) | 作为csf-1r抑制剂的杂环化合物及其应用 | |
| CN109476677B (zh) | 抗hcmv病毒化合物 | |
| JP6900406B2 (ja) | Akt阻害剤としてのジヒドロピラゾロアゼピン系化合物 | |
| CN115215861A (zh) | 一种芳杂环取代的炔烃类化合物及其制备方法和用途 | |
| HK40002597A (en) | Pde4 inhibitor | |
| HK40002597B (en) | Pde4 inhibitor | |
| EA038176B1 (ru) | Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в | |
| HK40001048B (zh) | S1p1激动剂及其应用 | |
| HK40004140A (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| HK40004140B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| HK40003826B (en) | Anti-influenza virus pyrimidine derivatives | |
| HK40003826A (en) | Anti-influenza virus pyrimidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: China Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province Applicant after: Nanjing Mingde New Drug Development Co.,Ltd. Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province Applicant before: MEDSHINE DISCOVERY Inc. Country or region before: China |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20260806 Address after: 518052 b37, 11th floor, Xihai Mingzhu building, No. 1 Taoyuan East Road, dawangshan community, Nantou street, Nanshan District, Shenzhen, Guangdong Patentee after: Shenzhen Jiake Biotechnology Co.,Ltd. Country or region after: China Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province Patentee before: Nanjing Mingde New Drug Development Co.,Ltd. Country or region before: China |